PEPG Stock Overview
A clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PepGen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.79 |
| 52 Week High | US$19.30 |
| 52 Week Low | US$3.72 |
| Beta | 1.69 |
| 11 Month Change | -26.99% |
| 3 Month Change | -27.69% |
| 1 Year Change | 33.14% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.32% |
Recent News & Updates
Recent updates
PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans
Aug 06
PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments
Jul 31The Prognosis For PepGen
May 20PepGen: Long Road Ahead
Jan 20Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?
Nov 13Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?
Jul 31We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation
Sep 07PepGen GAAP EPS of -$1.23 misses by $0.47
Aug 12Shareholder Returns
| PEPG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.0% | -1.4% | -1.9% |
| 1Y | 33.1% | 20.2% | 30.4% |
Return vs Industry: PEPG exceeded the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: PEPG exceeded the US Market which returned 30.8% over the past year.
Price Volatility
| PEPG volatility | |
|---|---|
| PEPG Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PEPG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PEPG's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 72 | James McArthur | pepgen.com |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
PepGen Inc. Fundamentals Summary
| PEPG fundamental statistics | |
|---|---|
| Market cap | US$211.18m |
| Earnings (TTM) | -US$89.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs PEPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEPG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$89.14m |
| Earnings | -US$89.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PEPG perform over the long term?
See historical performance and comparison